We found that GLP-1 RAs are superior to placebo for the prevention of MACE in T2DM patients with and without obesity, whereas SGLT-2 inhibitors show a tendency but do not outperform placebo in T2DM patients with obesity. The gene discussed is SLC5A2; the disease is obesity disorder.